In the study by Frewer et al., the levels of interleukin (IL)-24, a cytokine with potential tumor-suppressive activity, its receptor IL-22R, and the levels of lymphangiogenic factors, such as podoplanin, PROX1, and LYVE-1, were evaluated in breast cancer tissue samples. The gene discussed is LYVE1; the disease is breast carcinoma.